News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Jordi Remon: Alectinib vs crizotinib in 1st line in Asian patients with ALK+ NSCLC
Jorbi Remon/X
Dec 10, 2024, 14:09

Jordi Remon: Alectinib vs crizotinib in 1st line in Asian patients with ALK+ NSCLC

Jordi Remon, Thoracic oncologist at CIOCC Barcelona, shared on X:

“ALESIA Trial: Alectinib vs crizotinib in 1st line in Asian patients with ALK+ NSCLC. OS: NE alectinib vs 81 mo. crozotinib!! Yes with crizotinib. Difference not significant. What would be the CROWN trial (Lorlatinib vs Crizo) if comparator was alectinib?”

Jordi remon

alectinib cancer crizotinib Jordi Remon OncoDaily Oncology
Special Coverage
Opinion
Aug 21, 2025, 12:03
UICC Enhances Cancer Care with Nutrition and Psycho-Oncology Support
Voices
Aug 21, 2025, 11:40
FDA has Granted Full Market Approval for Papzimeos - NIH
Insight
Aug 21, 2025, 11:16
Kefah Mokbel: TAD Proven Safe with Effective Long-Term Outcomes for Breast Cancer Patients
Voices
Aug 21, 2025, 11:15
Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...
OncoDaily Pulse
Aug 21, 2025, 10:23
Archana Ajmera: Meet the Experts of VIRO 2025
OncoDaily Pulse
Aug 21, 2025, 10:08
Yüksel Ürün: Meet the Experts of VIRO 2025
Voices
Aug 21, 2025, 09:46
Pratiti Bandopadhayay: Urgent Need to Sustain Funding for Pediatric Brain Tumor Trials
Voices
Aug 21, 2025, 09:30
Jana Ellegast: Inflammatory Signaling in the Pathogenesis of AML
Insight
Aug 21, 2025, 09:02
Humaid Al-Shamsi: Outcomes of HSCT from Matched Related Donors in Pediatric Patients
Celebrities
Aug 21, 2025, 08:40
World’s Nicest Judge Frank Caprio Dies at 88 After Brave Battle with Pancreatic Cancer
Insight
Aug 21, 2025, 08:17
Weight Loss Trial Reports Success for Breast Cancer Patients at One Year Mark
Science
Aug 21, 2025, 06:29
Moazzam Shahzad: The Impact of MRD Status after Matched Donor alloHCT in AML